NeurogesX Announces FDA Acceptance To Review New Drug Application For NGX-4010 To Treat Post Herpetic Neuralgia (Medical News Today)
NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) to review its investigational product candidate, NGX-4010, for the management of pain due to post-herpetic neuralgia (PHN).

VITROS(R) 3600 Immunodiagnostic System For Laboratory Diagnostics Receives 510(k) Clearance From The FDA (Medical News Today)
Ortho Clinical Diagnostics announced 510(k) clearance from the United States Food and Drug Administration (U.S. FDA) for its VITROS(R) 3600 Immunodiagnostic System. This new high-capacity immunoassay system provides laboratories with a truly innovative solution to address their quality, labor and cost challenges.